Solid biosciences and phlox therapeutics announce strategic research collaboration focused on accelerating the development of new therapies for rare cardiac diseases

Charlestown, mass. and naarden, the netherlands, jan. 11, 2023 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, and phlox therapeutics, a biotech company pioneering a novel approach to gene therapies to alleviate and cure cardiomyopathies, today announced a strategic collaboration focused on genetic cardiac diseases. the research collaboration will target a severe form of genetic dilated cardiomyopathy (dcm) for which there is currently a significant unmet need for effective treatments.
SLDB Ratings Summary
SLDB Quant Ranking